{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:01:40Z","timestamp":1794844900731,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atogepant is approved for migraine prevention and has shown strong efficacy in clinical trials. However, its effectiveness following failure of anti-CGRP monoclonal antibodies (MAbs) has not been evaluated in large real-world populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter observational study conducted across Spanish headache units included adults with migraine who initiated atogepant after failure of \u2265\u20091 anti-CGRP MAb and had\u2009\u2265\u20093 months of follow-up. Baseline demographic and clinical variables were collected prospectively, with follow-up assessments at months 3 and 6. The primary outcome was the proportion of patients achieving a\u2009\u2265\u200950% reduction in monthly migraine days (MMD) at three months. Secondary outcomes included\u2009\u2265\u200930%, \u2265\u200975%, and 100% response rates; changes in headache days, pain intensity, acute medication use, and patient-reported outcomes; adverse events; treatment persistence; and factors associated with response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 252 patients were included (mean age 48.9\u2009\u00b1\u200912 years; 83.3% female; 80.6% with chronic migraine; 45.6% with continuous daily headache). Prior to atogepant, 39.7% had failed one anti-CGRP MAb, 27.0% two, 20.2% three, and 13.1% four. Median baseline MMD was 16, monthly headache days 27, and acute medication days 20. At 3 months, 44.4% achieved a\u2009\u2265\u200930% reduction in MMD, 29.7% \u226550%, and 11.7% \u226575%. Adverse events were reported in 52.5% of patients, most commonly constipation (30%) and nausea (25%). At three months, 26.2% had discontinued treatment (65.1% due to inefficacy, 28.8% due to intolerance). Treatment persistence at 180 days was 61% (95% CI 54 to 69%). A higher number of previously failed MAbs was independently associated with reduced odds of \u2265\u200950% response (RR 0.79, 95% CI 0.64 to 0.97). Moreover, a higher number of previously failed MAbs was associated with diminished improvements across multiple clinical endpoints, including headache frequency, intensity, acute medication use, and disability measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Atogepant may represent a viable treatment option for patients with migraine who have failed anti-CGRP MAbs. In this large real-world cohort, approximately one-third of patients achieved a\u2009\u2265\u200950% response, despite a treatment-refractory profile. However, the likelihood of response decreases with a higher number of previously failed MAbs, and mild adverse events are frequent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-025-02239-1","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T17:20:01Z","timestamp":1764350401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response"],"prefix":"10.1186","volume":"27","author":[{"given":"Albert","family":"Mu\u00f1oz-Vendrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Campoy-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Val\u00edn-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Casas-Lim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Fern\u00e1ndez-L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Santos-Lasaosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u00e9sica","family":"Gonz\u00e1lez Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gonzalez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Campdelacreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Portocarrero-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Cano S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Mar\u00eda","family":"Garc\u00eda S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"P\u00e9rez-de-la-parte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Moroll\u00f3n S\u00e1nchez-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"L\u00f3pez-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane","family":"M\u00ednguez-Olaondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"S\u00e1nchez-Soblechero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lozano Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Morales Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Andr\u00e9s L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Layos-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torres-Ferr\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Belv\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garcia-Azorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"D\u00edaz-de-Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel Luis","family":"Guerrero-Peral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Gago-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Huerta-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2239_CR1","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles A, Pozo-Rosich P (2019) Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394:1765\u20131774. https:\/\/doi.org\/10.1016\/S0140-6736(19)32504-8","journal-title":"Lancet"},{"key":"2239_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10194-022-01472-2","volume":"23","author":"X Wang","year":"2022","unstructured":"Wang X, Wen D, He Q et al (2022) Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J Headache Pain 23:105. https:\/\/doi.org\/10.1186\/s10194-022-01472-2","journal-title":"J Headache Pain"},{"key":"2239_CR3","doi-asserted-by":"publisher","unstructured":"Caronna E, Gallardo VJ, Egeo G et al (2024) Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry jnnp-2023-333295. https:\/\/doi.org\/10.1136\/jnnp-2023-333295.","DOI":"10.1136\/jnnp-2023-333295"},{"key":"2239_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s10194-023-01698-8","volume":"24","author":"M Waliszewska-Pros\u00f3\u0142","year":"2023","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Vuralli D, Martelletti P (2023) What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants? J Headache Pain 24:163. https:\/\/doi.org\/10.1186\/s10194-023-01698-8","journal-title":"J Headache Pain"},{"key":"2239_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/head.14439","volume":"63","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Reuter U et al (2023) Once-daily oral Atogepant for the long\u2010term preventive treatment of migraine: findings from a multicenter, randomized, open\u2010label, phase 3 trial. Headache: J Head Face Pain 63:79\u201388. https:\/\/doi.org\/10.1111\/head.14439","journal-title":"Headache: J Head Face Pain"},{"key":"2239_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385:695\u2013706. https:\/\/doi.org\/10.1056\/NEJMoa2035908","journal-title":"N Engl J Med"},{"key":"2239_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J et al (2020) Safety, tolerability, and efficacy of orally administered Atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol 19:727\u2013737. https:\/\/doi.org\/10.1016\/S1474-4422(20)30234-9","journal-title":"Lancet Neurol"},{"key":"2239_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M et al (2023) Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402:775\u2013785. https:\/\/doi.org\/10.1016\/S0140-6736(23)01049-8","journal-title":"Lancet"},{"key":"2239_CR9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","volume":"23","author":"C Tassorelli","year":"2024","unstructured":"Tassorelli C, Nagy K, Pozo-Rosich P et al (2024) Safety and efficacy of Atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol 23:382\u2013392. https:\/\/doi.org\/10.1016\/S1474-4422(24)00025-5","journal-title":"Lancet Neurol"},{"key":"2239_CR10","doi-asserted-by":"publisher","unstructured":"Vernieri F, Iannone LF, Lo Castro F et al (2025) Effectiveness and tolerability of Atogepant in the prevention of migraine: a real life, prospective, multicentric study (The STAR study). Cephalalgia 45. https:\/\/doi.org\/10.1177\/03331024251335927","DOI":"10.1177\/03331024251335927"},{"key":"2239_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-025-02068-2","volume":"26","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Egeo G, Pistoia F et al (2025) GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of Atogepant in migraine patients with multiple therapeutic failures. J Headache Pain 26:122. https:\/\/doi.org\/10.1186\/s10194-025-02068-2","journal-title":"J Headache Pain"},{"key":"2239_CR12","doi-asserted-by":"publisher","unstructured":"Jaimes A, Rodr\u00edguez-Vico J, Pajares O et al (2025) Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: the RESCUE study. Cephalalgia 45. https:\/\/doi.org\/10.1177\/03331024251346925","DOI":"10.1177\/03331024251346925"},{"key":"2239_CR13","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1-211 https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"2239_CR14","doi-asserted-by":"crossref","unstructured":"Little R, Rubin D (2019) Statistical analysis with missing data, 3rd ed. Hoboken (NJ): Wiley","DOI":"10.1002\/9781119482260"},{"key":"2239_CR15","doi-asserted-by":"publisher","first-page":"b2393","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JAC Sterne","year":"2009","unstructured":"Sterne JAC, White IR, Carlin JB et al (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338:b2393\u2013b2393. https:\/\/doi.org\/10.1136\/bmj.b2393","journal-title":"BMJ"},{"key":"2239_CR16","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/sim.6451","volume":"34","author":"S Jolani","year":"2015","unstructured":"Jolani S, Debray TPA, Koffijberg H et al (2015) Imputation of systematically missing predictors in an individual participant data meta-analysis: a generalized approach using MICE. Stat Med 34:1841\u20131863. https:\/\/doi.org\/10.1002\/sim.6451","journal-title":"Stat Med"},{"key":"2239_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-024-01736-z","volume":"25","author":"P Rizzoli","year":"2024","unstructured":"Rizzoli P, Marmura MJ, Robblee J et al (2024) Safety and tolerability of Atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials. J Headache Pain 25:35. https:\/\/doi.org\/10.1186\/s10194-024-01736-z","journal-title":"J Headache Pain"},{"key":"2239_CR18","doi-asserted-by":"publisher","unstructured":"G\u00f6bel CH, Heinze A, Heinze-Kuhn K et al (2025) Evaluating treatment success in CGRP antibody prophylaxis: a retrospective cohort study comparing monthly migraine days, MIDAS scores, and HIT-6 scores. Pain Ther. https:\/\/doi.org\/10.1007\/s40122-025-00784-w.","DOI":"10.1007\/s40122-025-00784-w"},{"key":"2239_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache: J Head Face Pain 61:1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache: J Head Face Pain"},{"key":"2239_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s10194-021-01366-9","volume":"22","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E et al (2021) In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain 22:151. https:\/\/doi.org\/10.1186\/s10194-021-01366-9","journal-title":"J Headache Pain"},{"key":"2239_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-024-01790-7","volume":"25","author":"J Hong","year":"2024","unstructured":"Hong J, Bin, Israel-Willner H, Peikert A et al (2024) Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies \u2013 insights from the German neurotransdata registry. J Headache Pain 25:90. https:\/\/doi.org\/10.1186\/s10194-024-01790-7","journal-title":"J Headache Pain"},{"key":"2239_CR22","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/head.14865","volume":"65","author":"A Jaimes","year":"2025","unstructured":"Jaimes A, G\u00f3mez A, Pajares O, Rodr\u00edguez-Vico J (2025) Effectiveness of switching strategies in <\u2009scp\u2009>\u2009CGRP\u2009monoclonal antibody therapy for migraine: A retrospective cohort study. Headache: J Head Face Pain 65:619\u2013630. https:\/\/doi.org\/10.1111\/head.14865","journal-title":"Headache: J Head Face Pain"},{"key":"2239_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/neurolint16010019","volume":"16","author":"R Suliman","year":"2024","unstructured":"Suliman R, Santos V, Al Qaisi I et al (2024) Effectiveness of switching CGRP monoclonal antibodies in Non-Responder patients in the UAE: a retrospective study. Neurol Int 16:274\u2013288. https:\/\/doi.org\/10.3390\/neurolint16010019","journal-title":"Neurol Int"},{"key":"2239_CR24","doi-asserted-by":"publisher","unstructured":"Overeem LH, Lange KS, Fitzek MP et al (2023) Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study. Front Neurol 14. https:\/\/doi.org\/10.3389\/fneur.2023.1154420","DOI":"10.3389\/fneur.2023.1154420"},{"key":"2239_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23:138. https:\/\/doi.org\/10.1186\/s10194-022-01498-6","journal-title":"J Headache Pain"},{"key":"2239_CR26","doi-asserted-by":"publisher","unstructured":"De Matteis E, Caponnetto V, Casalena A et al (2022) Cranial autonomic symptoms and response to monoclonal antibodies targeting the calcitonin gene-related peptide pathway: a real-world study. Front Neurol 13. https:\/\/doi.org\/10.3389\/fneur.2022.973226","DOI":"10.3389\/fneur.2022.973226"},{"key":"2239_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0333102419864507","volume":"40","author":"H Ghanizada","year":"2020","unstructured":"Ghanizada H, Al-Karagholi MA-M, Arngrim N et al (2020) PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia 40:57\u201367. https:\/\/doi.org\/10.1177\/0333102419864507","journal-title":"Cephalalgia"},{"key":"2239_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/14728214.2024.2317778","volume":"29","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, Ashina M, Martelletti P (2024) Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert Opin Emerg Drugs 29:57\u201364. https:\/\/doi.org\/10.1080\/14728214.2024.2317778","journal-title":"Expert Opin Emerg Drugs"},{"key":"2239_CR29","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","volume":"16","author":"J Hong","year":"2023","unstructured":"Hong J, Bin, Lange KS, Overeem LH et al (2023) A scoping review and Meta-Analysis of Anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals 16:934. https:\/\/doi.org\/10.3390\/ph16070934","journal-title":"Pharmaceuticals"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02239-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02239-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:07:06Z","timestamp":1781618826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-025-02239-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2239"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02239-1","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AMV and SCD have received honoraria from Abbvie, Amgen, Biogen, Bial, Chiesi, Janssen, Kern Pharma, Lilly, Lundbeck, Merck, Novartis, Organon, Pfizer, Roche, Sanofi, Teva, UCB, and Zambon. JCL has received honoraria from Abbvie, Lundbeck, Novartis, Organon, and Teva. IFL has nothing to disclose. NGG has nothing to disclose. SSL has received honoraria as a consultant for Abbvie, Organon, Pfizer, and Teva, and as a speaker for Abbvie, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Organon, Pfizer, and Teva. YGO has nothing to disclose. AGM has received speaker honoraria from Teva, Lilly, and Altermedica. Her salary has been partially funded by R\u00edo Hortega (CM21\/00178) and Juan Rod\u00e9s (JR23\/00005) fellowships from Instituto de Salud Carlos III and the European Union (ESF+) She is principal investigator of a research project funded by Instituto de Salud Carlos III (PI24\/01085), a board member of the Future Headache Experts (European Headache Federation), secretary of the RRFS (European Academy of Neurology), and coordinator of the junior Headache Group of the Spanish Society of Neurology. JC has nothing to disclose. LPS has nothing to disclose. LMCS has received honoraria from Lilly and Teva. SMGS has received honoraria from Lilly and Teva. AP has nothing to disclose. NMSM has received honoraria from Teva, Abbvie, Lilly, Novartis, Exeltis, Organon, Dr. Reddy\u2019s, and Almirall. ALB has received speaker and\/or clinical advisor honoraria from Novartis, Lilly, Teva, Lundbeck, Abbvie, Almirall, and Viatris. AMO has nothing to disclose. ASS has received honoraria from Lundbeck, Teva, Abbvie and Organon. ALR has received honoraria from Teva, Lundbeck, Dr. Reddy\u2019s, Abbvie, Lilly, and Novartis. CMH has received honoraria from Abbvie, Lundbeck, Teva, Pfizer, Lilly, and Organon. AAL has received honoraria from Abbvie, Lilly-Organon, Lundbeck y TEVA. ALR has received honoraria for medical education and consulting with Abbvie, Lilly, Lundbeck, Novartis, and Teva. EC has received honoraria from Novartis, Chiesi, Lundbeck, Medscape, and Lilly. His salary has been partially funded by R\u00edo Hortega and Juan Rod\u00e9s fellowships from Instituto de Salud Carlos III. He is junior editor for Cephalalgia. MTF has received honoraria as consultant or speaker for Allergan, Abbvie, Almirall, Chiesi, Eli Lilly, Novartis, Medlink, Teva, Organon and Pfizer. AA has received honoraria as consultant from Allergan-Abbvie, Novartis, Chiesi, and Medlink. PPR has received honoraria as consultant and speaker for Abbvie, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Pfizer, and Teva. Her group has received research grants from Abbvie, Novartis, Teva, Instituto de Salud Carlos III, EraNet Neuron, and FEDER. She has also received clinical trial funding from Abbvie, Amgen, Biohaven, Eli Lilly, Novartis, Pfizer, and Teva. She is Honorary Secretary of the International Headache Society, associate editor for Cephalalgia and Neurolog\u00eda, and founder of\n                      \n                      . She holds no pharmaceutical company stock. RB has received honoraria from Abbvie, Organon, TEVA, Orion, Lundbeck, Pfizer, Abbott, Cardiva, Medtronik, Adamed, Dr. Reddy, Prim, Noema, Almirall, Exeltis, Novartis and Lilly. DGA has nothing to disclose. JDT has nothing to disclose. ALGP has participated in advisory and speaker boards for Abbvie, Dr. Reddy\u00b4s, Eli Lilly, Lundbeck, Novartis, Organon, Pfizer, and Teva. ABGV has participated in scientific speeches and advisory boards for Abbvie, Teva, Pfizer, Lundbeck, Organon, Lilly, Novartis, and Almirall. MHV has received honoraria for advisory boards and collaborations as consultant, scientific communicator, speaker, and for research support and congress travel from Abbvie-Allergan, Novartis, Lilly, Almirall, Chiesi, Eisai, Exeltis, Kern Pharma, Menarini, Teva, and Zambon. His research group has received research grants from Abbvie-Allergan and funding for clinical trials from Lilly, Novartis, and Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}